Ledger.Open graph →
SEC Form D · filed April 19, 2018

Allogene Therapeutics, Inc

Offering
$411.8M
Sold
$411.8M
Exemption
Rule 506(b)
Industry
Biotechnology
Location
SOUTH SAN FRANCISCO, CA
Type
—

Rule 506(b): private placement to accredited investors, no public advertising.

People & firms on this filing (21)

David M. Bonderman · SOUTH SAN FRANCISCO, CADirectorTodd M. Sisitsky · SOUTH SAN FRANCISCO, CADirectorJoshua A. Kazam · SOUTH SAN FRANCISCO, CAExec · DirectorDavid M. Tanen · Flemington, NJExecFranz M. Humer · SOUTH SAN FRANCISCO, CADirectorArie M. Belldegrun · SOUTH SAN FRANCISCO, CADirectorJohn M. Deyoung · SOUTH SAN FRANCISCO, CADirectorRobert M. Abraham · SOUTH SAN FRANCISCO, CADirectorOwen M. Witte · SOUTH SAN FRANCISCO, CADirectorDavid M. Tanen · San Francisco, CAExecDavid M. Chang · SOUTH SAN FRANCISCO, CADirectorRobert M. Abraham · SOUTH SAN FRANCISCO, CADirectorOwen M. Witte · SOUTH SAN FRANCISCO, CADirectorDavid M. Bonderman · SOUTH SAN FRANCISCO, CADirectorTodd M. Sisitsky · SOUTH SAN FRANCISCO, CADirectorJoshua A. Kazam · San Francisco, CAExec · DirectorDavid M. Tanen · New York, NYExecDavid M. Chang · SOUTH SAN FRANCISCO, CADirectorFranz M. Humer · SOUTH SAN FRANCISCO, CADirectorArie M. Belldegrun · SOUTH SAN FRANCISCO, CADirectorJohn M. Deyoung · SOUTH SAN FRANCISCO, CADirector

Public SEC Form D (Reg D) filing. · View issuer on SEC EDGAR ↗